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Pg 2, abstract: recommend English editing of the results section. Some of the use of the singular sounds 
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compared sRAGE levels after women were classified according to the median value of EAT, VAT and SAT 
volumes or the WC cut off value of 80 cm. For group-wise comparison (three groups), ANOVA or Kruskal-
Wallis tests followed by Bonferroni or Dunns tests were used as appropriate. To test the univariate 
association between sRAGE and the other variables, Pearson (for normal-distributes data) or Spearman 
(for non-normal distributed data) correlation tests were used, as appropriate. Stepwise regression 
analysis was performed to test the independent association between sRAGE and indices of fat 
distribution. All statistical analyses were performed using STATISTIX 7.0 (Analitical Software, Tallahassee, 
FL) and GraphPAd Prism 5.0 biochemical statistical package (GraphPad Software, San Diego, CA). A p 
value < 0.05 was considered significant.” 
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Abstract 46 
 47 
Purpose Soluble receptor for advanced glycation end products (sRAGE) is a decoy receptor which 48 
sequesters RAGE ligands and acts as a cytoprotective agent. To date, it is unclear whether the lower sRAGE 49 
levels observed in obesity is are a marker of increased overall adiposity or reflects increases in particular fat 50 
depots. Therefore, we evaluated in healthy women the relationship among sRAGE and indicators of 51 
adiposity, including abdominal visceral (VAT) and epicardial visceral (EAT) adipose tissues, to explore the 52 
potential role of sRAGE as an earlier biomarker of cadiometabolic risk.  53 
Methods Plasma sRAGE levels wwereas quantified by an enzyme-linked immunosorbent assay in 47 healthy 54 
eumenorreich women. Total fat mass (FM) and fat-free mass were estimated with bioimpedance analysis. 55 
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Anthropometric measures and biochemical data were recorded. Subcutaneous adipose tissue (SAT), VAT 56 
and EAT volumes were measured by magnetic resonance imaging. 57 
Results Obese women had lower sRAGE levels compared to normal weight women. sRAGE levels was were 58 
also lower in women with a waist circumference (WC) larger than 80 cm. Correlation analyses indicated an 59 
strong inverse association of sRAGE with body mass index and FM. Concerning adipose tissue distribution,  60 
sRAGE inversely correlated with WC, EAT and VAT depots. In a multiple stepwise regression analysis, 61 
performed to emphasize the role of fat distribution, EAT volume was the only predictor of sRAGE. 62 
Conclusions Lower sRAGE levels reflects accumulation of visceral fat mainly at the epicardial level and  is 63 
present  in advance the appearing of metabolic complications in adult women. sRAGE quantification might 64 
be an early marker of cardiometabolic risk. 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
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Introduction 84 
 85 
Receptor for advanced glycation end products (receptor for AGE, RAGE) is a cell-surface protein initially 86 
identified as a receptor for N-carboxymethyllysine-modified proteins, one of the major AGE in vivo [1], but 87 
also able to bind other nonglycated molecules, like S100/calgranulin family of peptides, High Mobility 88 
Group Box 1 protein (HMGB1), amyloid-β peptide and macrophage-1 antigen (Mac-1) [2-4]. Ligand 89 
engagement of RAGE leads to the activation of the nuclear transcription factor NF-κB which results in the 90 
onset of the inflammatory response [5]. Besides the cell surface form, RAGE also exists as a soluble 91 
circulating molecule (sRAGE), a decoy receptor able to prevent ligand binding at cellular level and therefore 92 
the induction of the inflammatory response [6]. Some recent studies demonstrated that increased expression 93 
of the cell-surface form promotes inflammation, adipocyte hypertrophy and insulin resistance [7,8]. 94 
Concerning the soluble form, sRAGE has been determined to have an inverse association with obesity, 95 
metabolic syndrome, atherosclerosis, coronary artery disease (CAD) and diabetes [9-17]. These observations 96 
suggest sRAGE as a possible marker for metabolic dysfunction and risk. Conversely, in some studies on 97 
long-term diabetes (both type 1 and 2) increased sRAGE levels was were proposed as a predictive biomarker 98 
of cardiovascular diseases (CVDs) and all-cause of mortality [15,18,19]. In this regard, it needs to be pointed 99 
out that there are different circulating RAGE forms contributing to the overall sRAGE levels: the 100 
endogenous secretory RAGE (esRAGE), an alternatively-spliced form of RAGE, and the cleaved form of the 101 
membrane receptor, cRAGE [6,11-13,19-22]. What is measured and whether the different forms have the 102 
same activities may account for some of the differences between the studies. 103 
Accurate assessment of body fat distribution is considered critical for assessing the risk of CVDs, mainly 104 
CAD [23,24]. Although most attention has been traditionally given to the relationship among intra-105 
abdominal fat accumulation and CAD, in the last years epicardial adipose tissue (EAT), the visceral fat 106 
located around the heart, received great consideration mainly due to its anatomical proximity to the 107 
myocardium and its endocrine activity [25-28]. 108 
To date, it is unclear whether the lower sRAGE levels observed in obesity [9,12,16,17] is are a marker of 109 
increased overall adiposity or instead reflects increases in particular visceral fat depots, important in CVDs 110 
risk estimation. 111 
Formatted: Font color: Red
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Therefore, in a group of adult women without known metabolic disorders we evaluated the relationship 112 
among between sRAGE and indicators of adiposity, including abdominal subcutaneous (SAT), abdominal 113 
visceral (VAT) and epicardial visceral (EAT) adipose tissues,  to explore the potential role of sRAGE as an 114 
early biomarker of cadiometabolic risk.  115 
 116 
Materials and Methods 117 
 118 
Study population 119 
 120 
Forty-seven healthy women referred to the Service of Clinical Nutrition and Cardiometabolic Prevention at 121 
the I.R.C.C.S. Policlinico San Donato were enrolled in this study. Inclusion criteria were: female sex, age > 122 
18 years, eumenorrhea and signed written informed consent. Individuals who met the following criteria were 123 
not eligible for the study: body mass index (BMI) <18.5, chronic illnesses (hematological and rheumatic 124 
diseases, inflammatory bowel disease, chronic renal failure, hypercortisolism, diabetes mellitus, hyper or 125 
hypothyroidism), history of cancer, smoking, alcohol and drug abuse, contraindication to magnetic resonance 126 
imaging (MRI). The study protocol, conducted in accordance with the declaration of Helsinki as revised in 127 
2013, has been approved by the local ethics committee (ASL Milano 2, protocol 2732) and all participants 128 
signed an informed consent before enrollment.  129 
 130 
Blood collection 131 
 132 
Blood samples were collected after an overnight fasting into pyrogen-free tubes with 133 
ethylenediaminetetraacetic acid as anticoagulant. Plasma samples were separated after centrifugation at 1500 134 
g for 15 min and stored at -20°C until analyses.  135 
 136 
 137 
 138 
 139 
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Biochemical assays 140 
 141 
The quantitative determination of sRAGE concentrations was were performed by a commercial human 142 
sRAGE immunoassay kit (R&D System, Minneapolis, MN, USA) according to manufacturer’s instructions. 143 
The minimum detectable dose ranged from 1.23-16.14 pg/mL. The maximum intra- and inter-assay 144 
coefficient of variations were 4.8 and 8.3%, respectively. 145 
Other biochemical parameters were assayed as previously reported [23,29]. LDL-cholesterol was calculated 146 
with the Friedewald formula.  Homeostasis model assessment of insulin resistance (HOMA-IR) index was 147 
calculated as follows: HOMA-IR = fasting insulin [U/mL]  fasting glucose [mmol/L] /22.5 [30]. The 148 
formula used for the lipid accumulation  product (LAP) index was: (waist circumference [WC, cm] - 58)  149 
(triglycerides [TG, mmol/L]) [31]. 150 
 151 
Anthropometric measures 152 
 153 
All participant were measured in light clothing and without shoes. Weight and height were taken with 154 
standard scales and stadiometers and recorded to the nearest 0.1 kg and 0.5 cm, respectively. WC and hip 155 
circumference were taken with a flexible non-stretchable tape, according to WHO guidelines [32]. BMI and 156 
waist to hip ratio (WHR) were calculated.  157 
 158 
Bioimpedance analysis 159 
 160 
Whole body composition was estimated using the Tanita-BC-420-MA Body Composition Analyzer (BIA) 161 
(Tanita Europe B.V., Amsterdam, The Netherlands), in the morning, under standardized conditions 162 
(prohibition of: alcohol intake and intensive training during the twelve hours preceding the measurements, 163 
excessive food and drink intake the day before, food and drink intake during the four hours before the test, 164 
measurement during menstruation). Body composition, including body fat mass (FM), was estimated by BIA 165 
according to resistance and reactance values, which are measured by the system, and subject’s height, sex 166 
and age. 167 
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Quantification of EAT, VAT and SAT volumes by MRI 168 
 169 
MRI was used to determine epicardial fat volume, as previously reported [33,34]. All examinations were 170 
performed using a 1.5-T system (Magnetom Sonata, Siemens Medical Systems, Erlangen, Germany). 171 
Subjects remained positioned in the scanner during the entire examination and a dedicated 4-element phased-172 
array cardiac coil was used.  Images were acquired during repeated end-expiratory breath-holds. 173 
Electrocardiographically gated cine true fast imaging with steady-state precession sequences (true-FISP) 174 
were acquired (bright blood, time of repetition [TR]/time to echo [TE] 45/1.5 ms, slice thickness 8 mm, flip 175 
angle 65°, 1 excitation; no interslice gap) along the 4-chamber axis to cover the entire cardiac volume. EAT 176 
volume was measured using Argus VA50A (Leonardo, Siemens Medical Systems) on a remote workstation. 177 
Epicardial fat was measured as the fat deposition between the outer layer of the myocardium and the visceral 178 
layer of the pericardium. A radiologist manually segmented true-FISP images of the end-systolic cardiac 179 
cycle. The area corresponding to the epicardial fat of each slice was multiplied by slice thickness and then 180 
added each other to obtain the total volume [34]. MRI was also used to determine VAT and SAT [35]. 181 
During the same MRI examination, a true-FISP sequence was acquired with the following parameters: TE 182 
4.3ms, TR 2.15 ms and acquisition time 70 s, slice thickness 5 mm. The field of view was set to encompass 183 
both VAT and the SAT. Slices were obtained at the level of L4 vertebral body. VAT and SAT areas were 184 
identified by an experienced trained radiologist with a manual segmentation. 185 
 186 
Statistical analysis 187 
 188 
Qualitative variables are summarized as numbers and percentages;  quantitative variables are expressed as 189 
mean with standard deviation (SD) or median and interquartile range (IQR). The normality of data 190 
distribution was assessed by the Kolmogorov-Smirnoff test. For group-wise comparison, tT-test (two 191 
groups), or Mann-Whitney test (two groups)were used to compared sRAGE levels after women were 192 
classified according to the median value of EAT, VAT and SAT volumes or the WC cut off value of 80 cm. 193 
For group-wise comparison (three groups),  and ANOVA or Kruskal-Wallis tests (n groups) followed by 194 
Bonferroni or Dunns tests were used as appropriate. To test the univariate association between sRAGE and 195 
Formatted: Not Highlight
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the other variables, PPearson (for normal-distributes data) or SSpearman (for non-normal distributed data) 196 
correlation tests were used, to test the univariate correlation of sRAGE with variablesas appropriate. 197 
Stepwise regression analysis was performed to test the independent association between sRAGE and indices 198 
of fat distribution. All statistical analyses were performed using STATISTIX 7.0 (Analitical Software, 199 
Tallahassee, FL) and GraphPAd Prism 5.0 biochemical statistical package (GraphPad Software, San Diego, 200 
CA). A p value < 0.05 was considered significant. 201 
 202 
Results 203 
 204 
The characteristics of the individuals included in the study are presented in Table 1. Of the 47 women, 16 205 
(34%) were normal weight (BMI 18.5-24.9 kg/m2), 10 (21.3%) were overweight (BMI 25-29.9 kg/m2) and 206 
21 (44.7%) were obese (BMI ≥ 30 kg/m2). No women were taking drugs at time of enrollment. 207 
Obese womean had lower sRAGE levels (640.8 ng/mL, 423.2-1345.0 ng/mL) compared to normal-weight 208 
(1363.0 ± 693.2 ng/mL, p=0.022). No differences were observed between overweight (1389.0 ± 617.8 209 
ng/mL) and normal weight  women (Figure 1A and Table 1). 210 
After women participants were classifiedcation according to BMI, all the evaluated anthropometric 211 
parameters and indices of adipose tissue distribution, that is EAT, VAT and SAT, were statistically 212 
significantly higher in both overweight and obese groups compared to normal weight (Table 1). Fasting 213 
glucose and  fasting insulin levels were higher whereas HDL cholesterol lower in obese than normal weight 214 
group, but all in the normal ranges (Table 1).  We also observed an increase in HOMA-IR and LAP, two 215 
indicators of insulin resistance, according to the obesity status (Table 1). 216 
Concerning parameters of body fat distribution, we explored sRAGE levels after women classification were 217 
classified according to the median value of EAT (9.2 mm), VAT (21.65 mm) and SAT (300 mm) volumes or 218 
the established WC cut off value of 80 cm, which is used to predict cardiovascular risk in European women 219 
[36]. sRAGE levels was were lower in all the groups with the highest EAT, VAT or SAT volumes compared 220 
to the lowest (p < 0.05 for all) (Figure 1B, C, D). Lower sRAGE levels was were also observed in the group 221 
with WC above the cut off value of 80 cm (n=29) (p=0.048) (Figure 1E). 222 
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The association of sRAGE with anthropometric and fat distribution parameters was then evaluated using 223 
Pearson or Spearman correlation coefficients. sRAGE inversely correlated with BMI, FM, WC and hip 224 
circumference (Table 2). We also observed an inverse association of sRAGE with EAT (r =-0.426, p=0.003) 225 
and VAT (-0.341, p=0.025), but not with SAT volume (r=- 0.197, p=0.206) (Table 2). 226 
HOMA-IR and LAP were observed to be higher in women with depressed sRAGE levels but their 227 
correlations with sRAGE did not reach the statistical significance (HOMA-IR: r=-0.252, p=0.087;  LAP: r=-228 
0.252, p=0.085; Table 2). 229 
To emphasize the role of fat distribution, a multiple stepwise regression analysis was then used to investigate 230 
the influence of different adipose tissue compartments on sRAGE levels. FM and parameters of fat 231 
distribution that were significantly correlated in the univariate analysis were included in the model. EAT 232 
volume most correlated with sRAGE, whereas the other indices did not enter the model (Table 3). 233 
 234 
Discussion  235 
 236 
Our study suggests that, in a group of healthy women, lower sRAGE levels mainly reflects visceral fat 237 
accumulation at the epicardial level rather than total body fat or fat accumulation in other adipose tissue 238 
depots. Due to the role of EAT as an important risk factor for CVDs and the fact that our study population is 239 
composed by adult women without known metabolic diseases, the existing association observed among 240 
sRAGE and EAT suggest a potential role of sRAGE as an early marker of cardiometabolic complications. 241 
The inverse correlation among sRAGE and obesity has been suggested in previous studies performed using 242 
both in vitro models, RAGE knockout animals as well as in humans  and confirmed also by our study 243 
[8,9,12,16,17,37-39]. Monden et al. [8] described the role of RAGE in promoting adipocyte hypertrophy. 244 
They observed lower weight, lower epididymal adipose tissue weight and adipocyte size in RAGE-/- mice. 245 
In addition, they also described a direct effect of adenoviral RAGE over-expression in promoting 3T3-L1 246 
adipocyte hypertrophy. In the field of human studies, a recent paper from our group suggested that increasing 247 
expression of RAGE in EAT is associated with increased tissue thickness [40]. Concerning the circulating 248 
form, lower sRAGE levels was were associated with increasing BMI and metabolic syndrome, also in 249 
proportion to the number of metabolic components, including central obesity, hyperglycemia and blood 250 
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pressure [9,12,16,21,41-43]. Although these studies suggested the existence of an association between 251 
sRAGE and central obesity, they utilized WC as a marker of abdominal visceral fat accumulation, not the 252 
direct quantification of VAT volume. Differently, we were the first to explore the association among sRAGE 253 
levels and indicators of adiposity in a group of healthy premenopausal women, including indicators of 254 
visceral adiposity, such as VAT and EAT, directly quantified by MRI. It is well known that adipose tissue 255 
distribution, and not adipose tissue per se, is important in CVD risk estimation and in the last decade EAT 256 
received great consideration in this field mainly due to its anatomical proximity to the myocardium and its 257 
endocrine activity. 258 
Currently, there is no consensus on the ‘gold standard’ for the in vivo quantification of EAT and both 259 
computed tomography (CT), ultrasound and MRI techniques have been used to quantify cardiac fat [44]. 260 
Ultrasound is the most widely available, fastest and the least expensive technique for estimating cardiac fat 261 
[44] but has the limitation of not being truly volumetric and cannot directly quantify the volume of cardiac 262 
fat [45]. Moreover, using ultrasound, it is difficult to distinguish between EAT and pericardial adipose tissue 263 
and often this last rather than EAT thickness is reported. In addition, ultrasound evaluation of EAT may be 264 
difficult in overweight patients. CT provides a true volumetric visualization and quantification of EAT and 265 
pericardial adipose tissue and may provide a more accurate evaluation of fat tissue due to its higher spatial 266 
resolution compared with ultrasound and MRI [44,46] but provides a ionizing radiation exposure. The gold 267 
standard for the evaluation of total body fat as well as for ventricular volume and mass is MRI and so the use 268 
of MRI is a reliable choice for the assessment of EAT [47]. Moreover, there is a high correlation between 269 
measurement of EAT with echocardiography and MRI. [46]. For these reasons, in our study we decided to 270 
evaluate EAT with MRI, considering this technique reliable also in overweight and obese patients, without a 271 
radiation exposure. For the evaluation of VAT and SAT, the most reliable tools are CT and MRI. MRI can 272 
produce high quality cross-sectional images without ionizing radiation exposure. Therefore, MRI is the first-273 
choice exam for studies performed on young subjects . Total VAT volume of the abdominal compartment by 274 
MRI is the gold standard measurement for VAT but is expensive and a long-lasting exam [48]. Maislin et al. 275 
in a cohort of 826 subjects, including also overweight and obese subjects, demonstraed that VAT area 276 
estimated on a single axial MRI image is highly correlated with VAT volume and is an accurate surrogate for 277 
the total VAT volume. 278 
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Previous publications, also from our group, suggested the potential role of EAT in promoting / accelerating 279 
CAD and other CVDs [23,27,28,34]. To be noted, in the present study we just observed that EAT is the main 280 
fat depot influencing sRAGE levels. Considering that sRAGE has been previously suggested as a potential 281 
biomarker of metabolic complications and future cardiovascular events, our results prompted us to consider 282 
the increased accumulation of visceral fat at the epicardial level one potential explanation of the link between 283 
sRAGE and CVDs. To date, the mechanisms of interaction between sRAGE and obesity are still unclear and 284 
our results did not prove the causal-relationship between sRAGE and EAT. This remains an interesting area 285 
to explore in the future.  286 
The “healthy” characteristic of our group is probably the reason of the lack of association between sRAGE 287 
and the biochemical markers of CVD risk observed in other studies [16,43]. Only HOMA-IR and LAP 288 
indices showed a trend of correlation with sRAGE. This finding is a further evidence that sRAGE may be an 289 
early marker of metabolic dysfunction. Especially, since the individuals included in the study were young, 290 
healthy adults without diabetes, the trend towards higher HOMA-IR and LAP indices with lower sRAGE 291 
means that sRAGE could be indicative of organ fat which may predispose to insulin resistance and metabolic 292 
complications before any disease. 293 
Whether the same results are observable also in men need to be explored in future studies. 294 
 295 
In conclusion, in healthy obese womean without metabolic disease, lower sRAGE levels reflects 296 
accumulation of visceral fat mainly at the epicardial level and  is are present  in advance the appearing of 297 
metabolic complications. Due to the role of EAT as an important risk factor for CVDs and the consistent 298 
association herein observed with sRAGE in healthy women, sRAGE might be suggested as potential early 299 
marker of cardiometabolic risk. This needs to be further confirmed in large-scale population studies. 300 
 301 
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Figure legends 449 
 450 
Figure 1 451 
Evaluation of levels of soluble receptor for advanced glycation end products (sRAGE) according to body 452 
mass index (BMI), epicardial adipose tissue (EAT), visceral adipose tissue (VAT) and subcutaneous adipose 453 
tissue (SAT) median values and waist circumference (WC) cut off of 80 cm. 454 
A) After classification according to BMI, sRAGE levels was were lower in obese (OB) than normal weight 455 
(NW) women (OW). * = p < 0.05  (Kruskal-Wallis test). 456 
 B-C-D) Women were stratified into two groups on the basis of the median EAT, VAT and SAT volumes, 457 
respectively. sRAGE levels was were lower in all the groups with the highest volumes compared to the 458 
lowest. * = p < 0.05 (Mann-Whitney test for EAT and VAT; t-test for SAT). 459 
E) After classification according to the WC cut off value of 80 cm, sRAGE levels was were lower in the 460 
highest WC group (p < 0.05). * = p < 0.05 (Mann-Whitney test). 461 
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Table 1. 
Demographic, anthropometric and biochemical characteristics of participants included in the study as a whole group
and after classification according to body mass index.
NW OW OB
(n=16) (n=10)  (n=21)
Age (years) 30.1 ± 4.9 33.8 ± 6.4 34.3 ± 10.6
Obesity (n,%)
     NW
     OW
     OB
BMI (kg/m
2
) 22.0 ± 1.5 27.2 ± 1.1
c
35.4 ± 3.5
e,f
Waist (cm) 71.4 ± 5.0 84.0 (82.3-91)
a
102.4 ± 11.5
e
Hip (cm) 97.2 ± 4.0 104.5 ± 5.5
a
120.5 ± 7.4
e,f
WHR 0.7 ± 0.1 0.8 (0.8-0.9)
a
0.9 ± 0.1
e
Fatt mass (%) 25.7 ± 5.6 35.0 ± 2.8
e
44.1 ± 3.6
e,f
EAT volume (mL) 3.5 (1.9-7.8) 10.8 ± 4.2
a
13.8 ± 7.4
e
VAT volume (mL) 14.1 ± 10.1 23.2 (20.0-32.5)
a
36.7 ± 18.5
e
SAT volume (mL) 226.9 ± 73.0 294.0 ±18.9
a
377.9 ± 59.5
d,e
Fasting glucose (mg/dL) 77.0 (74.5-88.5) 85.3 ± 6.1 87.3 ± 7.9
a
Fasting insulin (mU/mL) 7.9 ± 3.3 10.7 ± 3.0 14.0 (8.6-21.9)
c
  
Total cholesterol (mg/dL) 192.6 ± 33.6 202.3 ± 42.5 179.9 ± 31.3
HDL cholesterol (mg/dL) 62.8 ± 17.2 61.5 ± 10.8 53.1 ± 14.7
c
LDL cholesterol (mg/dL) 105.1 ± 29.7 116.9 ± 40.3 108.5 ± 25.7
Triglycerides (mg/dL) 88.4 ± 32.9 119.7 ± 64.5 82.0 (67.5-106.5)
HOMA-IR 1.6 ± 0.7 2.3 ± 0.7 3.8 ± 2.7
c
LAP index 10.8 (6.8-19.3) 32.5 ±15.6
a
42.9 (25.8-58.5)
e
sRAGE 1363 ± 693.2 1389 ± 195.4 640.8 (423.2-1345)
a
Data are expressed as mean ± SD, median (25th-75th percentiles) or number and proportions. 
NW, normal weight; OW, overweight; OB, obese; BMI, body mass index; WHR, waist to hip ratio; EAT, epicardial adipose tissue;
VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; HOMA-IR, homeostatic model assessment of insulin resistance; 
LAP, lipid accumulayion product; sRAGE, soluble receptor for advanced glycation end products.
Comparison between BMI categories  was performed by ANOVA or Kruskal-Wallis tests  followed by Bonferroni or Dunns tests. 
a, p<0.05 vs.  NW; b, p<0.05 vs.  OW; c, p<0.01 vs.  NW; d, p<0.01 vs.  OW; e, p<0.001 vs.  NW; f, p<0.001 vs.  OW.
9.8 (6.7-15.2)
1020 (604.3-1633.0)
27.8 (13.2-43.8)
189.1 ± 35.0
60.8 ± 16.5
106.4 (89.3-124.7)
81.0 (65.0-118.8)
(n=47)
Healthy pre-menopausal women 
2.1 (1.3-3.2)
16, 34.0
10, 21.3
307.4 ± 88.2
35.3 ± 9.3
104.0 (98.5-120.0)
21.7 (12.9-40.0)
84.3 ± 8.1
33.3 ± 8.4
28.9 ± 6.6
88.0 ± 2.4
21, 44.7
10.0 ± 7.1
0.81 ± 0.1
Table 1
Table 2. Univariate association between plasma sRAGE, demographic, 
biochemical and body composition parameters in the study population
r p
Age -0.123 0.411
BMI -0.363 0.012
Waist -0.391 0.007
Hip* -0.416 0.004
WHR -0.238 0.111
EAT volume -0.426 0.003
VAT voume* -0.341 0.025
SAT volume -0.197 0.206
Fat mass -0.312 0.039
Fasting glucose -0.127 0.395
Fasting insulin* -0.254 0.107
Total cholesterol 0.070 0.614
HDL cholesterol 0.017 0.908
LDL cholesterol* -0.043 0.777
Triglycerides* 0.130 0.384
HOMA-IR* -0.252 0.087
LAP index* -0.254 0.085
Association between variables was explored using Pearson or Spearman (*) correlation coefficients. 
BMI, body mass index; WHR, waist to hip ratio; EAT, epicardial adipose tissue;
VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue;
HOMA-IR, homeostatic model assessment of insulin resistance; LAP, lipid accumulayion product.
Table 2
Table 3. Model of multiple regression analysis
VARIABLE B STD ERROR t p 
EAT volume -35,542 16,898 -2,103 0.042
VAT volume 4,203 7,683 0.547 0.588
Fat Mass -8,626 14,590 -0.591 0.558
EAT, epicardial adipose tissue; VAT, visceral adipose tissue.
Table 3
